Introduction
Acute promyelocytic leukemia (APL) is a subtype of acute myelogenous leukemia, representing 5-8% of acute myelogenous leukemia cases in adults. At the genetic level, APL is characterized by a specific chromosomal rearrangement between the retinoic acid (RA) receptor-a (RARA) and the promyelocytic leukemia (PML) genes. [1] [2] [3] The resulting chimeric protein, PML-RARA, acts as a dominant negative inhibitor of normal retinoid receptor function. It locates to promoters normally regulated by RARA, aberrantly recruits co-repressor proteins, and thereby inhibits the RARA-mediated gene expression. On the cellular level, the result is a block in granulocytic differentiation and an accumulation of myeloid progenitors arrested at the promyelocyte stage. APL patients are treated with therapeutic doses of all-trans RA, a vitamin A derivative that activates RARA and circumvents the differentiation block. 4 Unfortunately, although treatment with RA alone results in a complete remission, the reprieve is not long-lasting, as RA resistance develops in vivo, 5 a phenomenon that can be modeled in vitro. 6 Acquired mutation in the PML-RARA oncoprotein is one source of RA-resistant APL. Studies on the PML-RARA protein in RA-resistant patient cells or cell lines established that roughly 33% possessed a mutation in the ligand-binding domain of the RARA portion of the fusion protein, resulting in a dysfunctional PML-RARA that is unable to respond to pharmacological doses of RA. [7] [8] [9] [10] However, the mechanisms of acquired resistance in the remaining 67% are undefined. The cells continue to express wild-type PML-RARA, yet are resistant to RA-induced differentiation.
In vitro-derived RA-resistant cell lines are useful experimental models for the study of mechanisms of RA resistance in APL. Our lab has previously isolated three RA-resistant subclones from the parental RA-sensitive cell line NB4, denoted NB4-MR2, NB4-MR4 and NB4-MR6. 11, 12 Consistent with the pattern in other models of RA-resistance, one of these resistant subclones, NB4-MR4, contains a mutation in the ligand-binding domain of PML-RARA, whereas the other two retain wild-type PML-RARA expression. 12 We have reported that resistance to RA-mediated transcription and differentiation in these cell lines is associated with enhanced binding of corepressor complexes to PML-RARA. 11 We furthered this observation by identifying topoisomerase II beta (TOP2B) as a novel member of these complexes. In addition, we showed that TOP2B inhibits RAinduced gene expression and granulocytic differentiation by negatively modulating RARA transcriptional activity. 13 Type II topoisomerases catalyze changes in the topological state of DNA by generating transient breaks in double-strand DNA. 14, 15 Owing to their DNA cleavage properties, TOP2s serve as target of antineoplastic agents, including DNA damaging agents. 16 Two isoforms of TOP2 (A and B) exist in mammals. TOP2B is a phosphoprotein in which most of the phosphorylation sites have been mapped to the C-terminal domain and are thought to be mostly serine or threonine residues. 17 Sequence analysis of TOP2 phosphorylation sites revealed 30 possible protein kinase C (PRKC) sites and 40 casein kinase II sites.
14 However, the functions of TOP2B's phosphorylation sites have not yet been characterized and the identification of possible phosphorylation sites responsible for TOP2B stability has remained elusive.
RA treatment leads to an increase of TOP2B protein levels in hematopoietic cells during differentiation. 18 Interestingly, this correlates with an increase in TOP2B protein stability and phosphorylation levels, 18 although the exact mechanism by which RA upregulates and stabilizes TOP2B protein levels in differentiating cells has not been determined. Previously, we demonstrated that increased TOP2B levels mediate RA resistance by inhibiting RA-induced gene expression and subsequent maturation toward granulocytes in APL cell lines. Consistent with this finding, the RA-resistant NB4-MR2 subline has comparatively higher basal TOP2B protein levels. 13 Interestingly, RA leads to increased levels of TOP2B protein in the RAsensitive NB4 cell line, suggesting the possibility of a negative feedback loop. We speculated that RA may activate specific kinases that lead to increased phosphorylation levels of TOP2B, thereby increasing its stability and decreasing its rate of degradation. In this study, we investigate the mechanism by which TOP2B protein levels are regulated in APL cells.
Materials and methods

Materials
RPMI 1640 and fetal bovine serum were purchased from Wisent (St Bruno, QC, Canada). All-trans RA and 4a-phorbol 12-myristate 13-acetate (PMA) were obtained from SigmaAldrich (St Louis, MO, USA). Rottlerin was purchased from Biomol (Plymouth Meeting, PA, USA). The PRKCD pSUPER short hairpin RNA-producing plasmid (Oligoengine, Seattle, WA, USA) was directed against the following target sequence: 5 0 -AAACTCATGGTTCTTGATGTAGTGG-3 0 . The PRKCD kinase dead (PRKCDKD) construct was kindly provided by Dr Trevor J Biden (Garvan Institute of Medical Research, Sydney, Australia).
Cell culture
Derivation of the RA-resistant cell line NB4-MR2 from the parental APL cell line NB4 was previously described. 11 All cell lines were maintained in RPMI-1640 supplemented with 10% fetal bovine serum.
Western blot analysis
Cell lysates were diluted 1:1 with 2 Â SDS sample buffer. Proteins were fractionated by electrophoresis on 10% SDS-polyacrylamide gels and transferred onto nitrocellulose membranes (Bio-Rad Laboratories, Mississauga, ON, Canada). Membranes were probed with antibodies against TOP2B (catalogue no. 611493, BD Biosciences, San Diego, CA, USA), PKCD (catalogue no. 610398, BD Biosciences), PRKCD phospho-threonine 505 (catalogue no. 3974S, Cell Signaling, Beverly, MA, USA) and b-actin (catalogue no. A5441, Sigma-Aldrich). The resulting signals were detected using the enhanced chemiluminescence (Amersham Pharmacia, Piscataway, NJ, USA) system.
Decatenation assay
TOP2B enzymatic activity was assayed by measuring the decatenation of kinetoplast DNA. A standard assay using 2 mg nuclear lysates was carried out according to the manufacturer's protocol (TopoGEN, Port Orange, FL, USA). Samples were resolved by electrophoresis on a 1% agarose gel containing ethidium bromide. Reaction products were visualized and photographed on a ultraviolet transilluminator using the ChemiGenius 2 imaging system (Syngene, Frederick, MD, USA).
Transient transfections
NB4 cells (1 Â 10 7 cells/transfection) were transfected by electroporation with 5 mg of the reporter plasmid bRARE-tkchloramphenicol acetyltransferase, with or without the pTB114 plasmid, which contains the full-length TOP2B isoform fused to green fluorescent protein in the pEGFP-C3 vector as previously described. 19 Following electroporation, cells were replenished in media, and grown for 48 h in the absence or presence of RA. Chloramphenicol acetyltransferase activity was measured by means of a modified protocol of the organic diffusion method. 20 The chloramphenicol acetyltransferase counts were normalized with protein concentration to obtain the relative chloramphenicol acetyltransferase activity.
RNA extraction and analysis
Total mRNA was isolated using the TRIzol method (Invitrogen, Carlsbad, CA, USA). cDNA was generated from 5 mg total RNA using random primers and SuperScript II reverse transcriptase (Invitrogen). CEBPE and CYP26A1 mRNA levels were assessed by quantitative real-time PCR analysis using Power SYBR green master mix (Applied Biosystems, FosterCity, CA, USA) with the following primer sets: CEBPE: sense 5 0 -CGGCTGGCCCCTTAC AC-3 0 , antisense 5 0 -AGCCGGTACTCAAGGCTATCTTT-3 0 ; and CYP26A1: sense 5 0 -GACATGCAGGCACTAAAGCAAT-3 0 , antisense 5 0 -CACTGGCCGTGGTTTCGT-3 0 . cDNA was amplified for RIGI using a Taqman hybridization probe and Taqman Fast Master Mix (Applied Biosystems). DDC t values were normalized with those obtained from the amplification of endogenous glyceraldehyde-3-phosphate dehydrogenase mRNA. Quantitative real-time PCR was performed on the 7500 Fast Real-time PCR system (Applied Biosystems) using standard parameters and analyzed using relative quantification with dimethylsulfoxidetreated NB4 cells as the calibrator.
Immunofluorescence
NB4 and NB4-MR2 cells were treated for 18 h with either 1 mM RA, 1 mM Rottlerin, or the combination. Cytospin preparations were fixed with 4% paraformaldehyde and stained with mouse anti-PML antibody (5E10 antibody from Dr R van Driel, University of Amsterdam, Amsterdam, the Netherlands) as previously described. 21 
Morphology
Morphological changes in NB4 and NB4-MR2 cells were evaluated using conventional light-field microscopy of GiemsaWright (Sigma-Aldrich)-stained cytosmears.
Differentiation assays
Cells to be used for fluorescence-activated cell sorting analysis of differentiation markers and in nitro-blue-tetrazolium reduction assays were seeded at 3 Â 10 4 cells/ml in 5 ml media in six-well plates. Immunofluorescence staining of the cell surface myeloid-specific antigen CD11c (PharMingen, Mississauga, ON, Canada) was assessed by flow-assisted cell cytometry and performed according to the antibody manufacturer's specifications using the FACSCalibur flow cytometer (BD Biosciences). Background staining was controlled using an isotype control PE-conjugated mouse IgG1 (PharMingen). In each sample, viable cells were gated, and expression of CD11c surface markers of 1 Â 10 4 cells was evaluated. Nitro-blue-tetrazolium assays were performed as previously described. 22 PKCd regulation of topoisomerase IIb in APL S McNamara et al
Results
Activation of PKCD correlates with increased TOP2B protein levels
A recent study established that protein kinase C delta (PRKCD), a member of the novel subgroup of the PRKC family of serine/ threonine kinases, interacted with the TOP2A protein. 23 This association led to increased protein expression of TOP2A and was dependent on the kinase activity of PRKCD. PRKCD is the most abundant PRKC isoform found in hematopoietic cells. 24 It is activated in response to platelet-derived growth factor, PMA and RA. 25 It is of interest that RA, implicated in TOP2B stability and phosphorylation, 18 can induce activation of PRKCD. 25, 26 As the two isoforms of TOP2 have 70% amino-acid sequence identity, we therefore hypothesized that PRKCD may be the kinase responsible for the accumulation of TOP2B protein by RA, and may also cause the higher endogenous TOP2B levels in the NB4-MR2 cell line.
We asked whether activation of PRKCD by RA correlates with increased TOP2B levels in both NB4 and NB4-MR2 cell lines. By western blot analysis we observe that RA induction of TOP2B protein levels and activation of PRKCD, as measured by phosphorylation at threonine 505 (PRKCD pT505), occur with similar timing (Figure 1a ). Consistent with previously published data, 25 total PRKCD levels are not significantly different in the two cell lines, and remained the same before, and after, RA treatment. Most strikingly, NB4-MR2 cells show substantially increased basal levels of PRKCD pT505, when compared with NB4. This finding corresponds to the increased basal levels of TOP2B also seen in this cell line. We then asked whether other activators of PRKCD would have a similar effect. We found that treatment with the PRKC activator PMA for 2 h increased both PRKCD pT505 and TOP2B levels in both cell lines (Figure 1b ).
Interestingly, PMA and RA activate PRKCD at different time points, 2 and 24 h, respectively. This correlates with the observed timing of increased expression of TOP2B by these two agents. These results suggest that the hyperactive PRKCD may mediate the increased levels of TOP2B in the NB4-MR2 cell line.
Inhibition of PRKCD leads to decreased TOP2B protein levels
To further test our hypothesis that PRKCD regulates TOP2B levels in NB4 and NB4-MR2 cells, we tested the effects of PRKCD inhibition on TOP2B protein levels. Treatment of NB4 and NB4-MR2 cells with increasing concentrations of Rottlerin, decreased the levels of TOP2B protein in a dose-dependent manner (Figure 2a) . Rottlerin has been reported to be a selective PRKCD inhibitor [27] [28] [29] and has been used in many studies to implicate PRKCD in a variety of cancers, including hematological malignancies. 25, [30] [31] [32] [33] There have been published reports that Rottlerin might have additional effects, 34, 35 and we therefore used additional approaches to confirm our initial findings. In accordance with the pharmacological inhibition of PRKCD, targeted knockdown of PRKCD in NB4-MR2 cells with short hairpin RNA, as well as by expression of a dominant negative inhibitory form of PRKCD (PRKCDKD), resulted in reduction of TOP2B levels (Figures 2b and c) . In contrast, Go6976, an inhibitor of the conventional PRKC isoforms (A, B, G), 28, 29, 36 had no effect on TOP2B protein levels (Figure 2d ). This further supports out hypothesis that TOP2B regulation is dependent on the PRKCD isoform.
PRKCD modulatesTOP2B catalytic activity
On the basis of the evidence that activation of PRKCD regulates TOP2B levels, we next examined the enzymatic consequence of this proposed regulation. Type II topoisomerases alter the topological state of double-strand DNA by cleaving and religating DNA strands. Previous reports suggested that the decatenation activity of TOP2A is enhanced by means of phosphorylation by both PRKCD 23 and casein kinase II. 37 To monitor the decatenation activity of TOP2B, we assayed its ability to decatenate kinetoplast DNA, a interlocked network of DNA rings made up of several thousand 2.5-kb monomers and a few larger maxicircles. 38 We incubated the kinetoplast DNA substrate with nuclear extracts from NB4 and NB4-MR2 cells and resolved the products by agarose gel electrophoresis. Here, we observed that decatenation activity was substantially enhanced (Figure 2e, lanes 1-4) after treatment with RA. The RA-induced activation is PRKCD-dependent, as inhibiting PRKCD with Rottlerin prevented RA from inducing decatenation activity in the cell line. Interestingly, nuclear extracts from NB4-MR2 cells possessed higher basal decatenation activity (Figure 2e, lanes 5-8) , reflective of their higher TOP2B and activated PRKCD protein levels. Stimulation with RA did not enhance this activity, while Rottlerin treatment decreased it below basal levels.
PRKCD inhibition decreases TOP2B protein stability
We previously determined that there is no significant difference in basal TOP2B mRNA levels in the NB4-MR2 cell line versus the NB4 cell line. 13 To determine whether the increased TOP2B protein levels observed in NB4-MR2 cells was due to increased protein stability, TOP2B protein levels were measured by immunoblotting after cycloheximide-mediated translation (Figure 3a,  lanes 1-4) , no detectable degradation was observed in NB4-MR2 cells until 24 h (Figure 3b, lanes 1-4) .
We next sought to examine whether a hyperactive PRKCD may be responsible for the increased stability of the TOP2B protein in the NB4-MR2 cell line. Thus, we measured the rate of TOP2B degradation after PRKCD inhibition by treating NB4 and NB4-MR2 cells with either the vehicle, dimethylsulfoxide, or Rottlerin. Twenty-four hours after treatment, the cells were incubated with cycloheximide, and, at the indicated times, cell lysates were harvested. Western blot analysis shows increased TOP2B protein degradation on PRKCD inhibition in both cell lines. In the NB4 cell line, we observe a significant decrease of TOP2B after inhibition of PRKCD, as compared with dimethylsulfoxide treatment (Figure 3a, lanes 5-8) . Importantly, in the NB4-MR2 cell line, at 24 h cycloheximide treatment, we observed an 80% decrease in TOP2B levels when PRKCD is inhibited, compared with only a 20% decrease in the untreated sample (Figure 3b, lane 4 vs lane 8) . This considerable decrease in TOP2B protein levels at 24 h suggests that PRKCD contributes to the increased TOP2B stability in the NB4-MR2 cell line. Of note, because of the increased levels of TOP2B in the NB4-MR2 cell line, a higher concentration of Rottlerin (2 mM) was required for downregulation of TOP2B. Despite decreasing TOP2B protein levels in both cell lines at 24 h, Rottlerin treatment results in an increase in TOP2B transcript at this same time point (Figure 3c, first column) . In addition, actinomycin D time course assays following the 24 h dimethylsulfoxide or Rottlerin treatment were carried out to rule out variability in TOP2B mRNA stability (Figure 3c) . No appreciable decrease in mRNA stability due to treatment with Rottlerin was observed. Surprisingly, chemical inhibition of PRKCD resulted in an increased TOP2B mRNA expression in both the NB4 and NB4-MR2 cell lines, while simultaneously decreasing the amount of TOP2B protein, suggesting a possible positive feedback mechanism. Figure 2 PRKCD regulates TOP2B protein levels and catalytic activity. (a) A decrease in TOP2B protein levels with increasing concentrations of Rottlerin was observed in both the NB4 and NB4-MR2 cell lines. Total nuclear protein was subjected to western blotting using a TOP2B antibody. (b) NB4-MR2 cells were transfected with scrambled short hairpin RNA (shRNA) or a shRNA against PRKCD. Total levels of TOP2B and PRKCD protein were analyzed by western blotting. (c) The kinase activity of PRKCD is required for TOP2B protein stability. NB4 and NB4-MR2 cells were transfected with either an empty vector (EV) or a vector expressing a kinase dead PRKCD (PRKC KD). (d) NB4 and NB4-MR2 cells were treated with Go6976 and Rottlerin. To observe a decrease in TOP2B protein levels, total nuclear proteins were subjected to western blotting using TOP2B antibody. b-Actin was used as a loading control for (a-d). (e) TOP2B-mediated decatenation of kinetoplast DNA (kDNA) is PRKC-dependent. TOP2B activity was measured by decatenation of kDNA to nicked open circular and relaxed closed circular DNA. A representative image of a 1% agarose gel (ethidium bromide-stained) is shown.
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Inhibition of PRKCD relievesTOP2B-mediated repressive effects on RA target genes
We have previously shown that TOP2B overexpression efficiently represses RA-induced gene expression. 13 To test whether PRKCD inhibition could alleviate the repressive effects of increased TOP2B levels on gene expression, we performed transient co-transfections with an RARE-reporter gene and a TOP2B overexpression vector (pTB114) in NB4 cells. RA treatment, in the absence of TOP2B overexpression, strongly induces RARE reporter gene transcription. Upon TOP2B overexpression, we observed a repression of RA-induced RARE reporter gene activation (Figure 4a) . However, the addition of Rottlerin restored induction of the RARE reporter gene by RA.
To confirm that PRKCD inhibition overcomes repression of RA responsive genes, we treated NB4 and NB4-MR2 cells with Rottlerin, RA and the combination and measured mRNA levels of the RA target genes, CEBPE, CYP26A1 and RIG-I. Increased mRNA induction of all three genes was observed in both cell lines with the combination treatment as compared with RA or Rottlerin alone (Figure 4b ).
Inhibition of PRKCD restores sensitivity to RA-induced differentiation in the NB4-MR2 cell line
Our data that PRKCD inhibition overrides the transcriptional repression exerted by TOP2B on RA-target genes led to the hypothesis that this inhibition would then be able to abolish the differentiation block in the NB4-MR2 cell line. In normal cells, PML locates to punctuate structures known as PML nuclear bodies, whereas in APL cells PML-RARA expression disrupts these structures and disperses PML into nuclear microspeckles. Treatment with RA reverses this abnormal nuclear PKCd regulation of topoisomerase IIb in APL S McNamara et al localization. 39 We first assessed PML staining by immunofluorescence in NB4 and NB4-MR2 cells treated for 18 h either with RA, Rottlerin or the combination (Figure 5a ). Cells were stained with anti-PML antibodies and counterstained with 4 0 ,6-diamidino-2-phenylindole to confirm nuclear staining (data not shown). In the untreated NB4 and NB4-MR2 cells, immunofluorescence showed a diffuse PML nuclear staining. We saw that RA alone and the combination of RA and Rottlerin PKCd regulation of topoisomerase IIb in APL S McNamara et al are both sufficient to cause larger PML nuclear bodies to form in the RA-sensitive NB4 cells. However, in the NB4-MR2 cell line, only the combination treatment led to the re-establishment of PML nuclear bodies. To extend and confirm these results, we performed morphological analysis of both cell lines treated for 5 days. Figure 5b demonstrates that the NB4-MR2 cells only differentiate after exposure to both RA and Rottlerin. The granulocytic maturation pattern was similar for all the differentiated cells, with polylobular nuclei, chromatin condensation and a decreased nuclear:cytoplasmic ratio.
Next, we examined expression levels of a cell surface marker associated with granulocytic differentiation (Figure 5c ) after 5-day treatment. As expected, RA alone is enough to stimulate significant CD11c expression in NB4 cells, whereas the same treatment in NB4-MR2 cells generates only a modest increase in expression. In addition, with Rottlerin alone there is a slight increase in CD11c expression in both cell lines. However, only in the presence of both RA and Rottlerin do we observe a robust increase in CD11c expression levels in the NB4-MR2 cell line.
As a final measure of the ability of PRKCD inhibition to overcome the differentiation block in APL cells, we performed a nitro-blue-tetrazolium reduction analysis. Rottlerin alone had little discernible effect on differentiation in either cell line. Again, the effect of the combination is greater than either agent alone; RA and Rottlerin co-treatment leads to significant nitroblue-tetrazolium reduction within 5 days (Figure 5d ). This is consistent with the immunofluorescence, morphology and CD11c data, where only a moderate increase in terminal differentiation was observed in the NB4-MR2 cell line in response to 10 À6 M RA after 5 days. The published report establishing that RA induces PRKCD activation 25 also presents data that inhibition of PRKCD by Rottlerin reversed RA induction of cd11b cell surface expression in the NB4 cell line, suggesting an opposite effect on PKCd regulation of topoisomerase IIb in APL S McNamara et al differentiation than was found here. We therefore undertook additional experiments to show that the combination of RA and Rottlerin induced differentiation in both the NB4 and NB4-MR2 cell lines. The combination treatment was more active in regard to the differentiation induction than either agent alone, as evaluated by all four criteria tested. To our knowledge, these data are the first to define PRKCD as a negative regulator of RAinduced gene regulation and differentiation toward granulocytes. We thus conclude that the hyperactive PRKCD in the NB4-MR2 cell line leads to enhanced TOP2B levels, which blocks the differentiation pathway toward granulocytes.
Discussion
The amount of an active protein available to carry out defined physiological functions is a major player in governing cell growth and proliferation. Our studies begin to uncover the mechanisms and ramifications of TOP2B protein regulation. We show that activation of PRKCD, by RA and PMA, leads to increased levels of TOP2B protein and conversely, inhibition of PRKCD correlates with decreased levels of TOP2B. We were the first to report that increased levels of TOP2B protein can mediate resistance to RA in APL cell lines. 13 That observation is now furthered by this report demonstrating that a hyperactive PRKCD is responsible for increased TOP2B levels in the RA-resistant cell line, NB4-MR2, and hence, ultimately contributes to RA resistance.
Both of the human topoisomerase II isoforms, TOP2A and TOP2B, are phosphorylated at several sites, primarily in the C-terminal domain. [40] [41] [42] Some specific phosphorylation sites and their functional consequences have been mapped for TOP2A, [43] [44] [45] [46] and a few, but not all, of the phosphoacceptor sites are conserved between the A and B isoforms. However, little is currently known about the ramifications of TOP2B phosphorylation. Potential functional roles for site-specific phosphorylation have been hinted at by several groups demonstrating hyperphosphorylation of TOP2B in doxorubicinresistant HL-60 cells 47 and phosphorylation during RA-induced differentiation of wild-type HL-60 cells, which correlated with a slower degradation rate of TOP2B protein. 18 The latter observation is now made more concrete by the research contained herein showing increased protein degradation on PRKCD inhibition. There are examples of phosphorylation increasing the metabolic stability, and consequently the activity, of a protein, as has been shown for the transcription factors p53 48 and c-fos. 49 Our assessment of decatenation ability confirms that TOP2B catalytic activity is considerably enhanced after activation of PRKCD and abrogated after inhibition of PRKCD. These results suggest that TOP2B be introduced into a family of proteins whose functional activity is managed through phosphorylation-dependent stability. However, no increase in total TOP2B phosphorylation after RA treatment, or conversely, no decrease with PRKCD inhibition, was observed in 32 P-labeling experiments (data not shown). We speculate that this might be due to changes in only a few of the many possible TOP2B phosphoacceptor sites, which would not affect the overall phosphorylation signal of the protein. Our ongoing studies aim to identify the specific TOP2B residues of PRKCD-mediated phosphorylation in order to characterize their functional role.
RA has been shown to directly bind the different PKC isoforms, including PRKCD. 50 Given the late timing of PRKCD activation after RA treatment, it is reasonable to hypothesize that RA is not acting directly on PRKCD and that another kinase might lie upstream in the pathway. Several MAP kinases have been previously shown to be involved in the response to RA. 51, 52 In particular, the p38 MAP kinase is phosphorylated and activated by RA treatment in NB4 cells 53 and PRKCD phosphorylation at Thr505 was recently shown to be dependent upon p38. 54 However, RA activates many complex signaling cascades that may also lie upstream of PRKCD and TOP2B. Indeed, future directions will aim to elucidate more clearly the entire signaling pathway leading to TOP2B regulation.
We previously found that TOP2B is overexpressed in the RAresistant APL cell line, NB4-MR2, 13 and TOP2B has also been found to be overexpressed in acute myeloid leukemia 55 and lymphoma 56 patients. However, mechanistic data on the causes of this upregulation have been lacking. Given that TOP2B is a target of many anticancer agents, its increased expression can enhance the cytotoxic activity of these agents in tumor cells. [57] [58] [59] [60] In particular, RA-resistant APL cells with excess TOP2B protein may respond better to treatment with anthracyclines. This hypothesis is supported by data from the clinic; when RA is co-administered with anthracycline-based therapy, APL patients have improved remission and survival rates. 61 On the other hand, in the context of leukemic differentiation, increased levels of TOP2B protein has an inhibitory effect on RA-induced differentiation and apoptosis. 17 It is also of general interest to mention that other RA targets are regulated in a similar manner as TOP2B in cancer cells: the transcription factor SOX9, 62 the myeloid transcription factor CEBPE, 63 the growth inhibitory protein IGFBP-3 64 and the translation repressor 4E-BP2 65 are all regulated by RA. Specifically, the basal level of expression of these proteins is low, but inducible in RA-sensitive cells, whereas in some RA-resistant cell lines, the basal level of expression is constitutively high and is only minimally further induced upon RA treatment. It had been shown that transcriptional activation by nuclear receptors requires a signal-dependent exchange of co-activators and corepressors. 66, 67 The deregulated TOP2B levels may negatively affect RA signaling at the level of coregulator cycling, either by preventing efficient dissociation and/or degradation of the corepressor complex or by inhibiting recruitment of the co-activator complexes, even in the presence of pharmacological doses of RA. A similar mechanism has recently been proposed for another repressor of RA signaling. 68 The possibility does exist that increased TOP2B levels are mere bystanders to the development of resistance. However, we feel that cumulatively our data support the model where TOP2B is a more active mediator of resistance, as inhibition of TOP2B, either directly 13 or indirectly by PRKCD, re-establishes sensitivity to RA-induced differentiation.
TOP2B protein levels can have an impact on both sensitivity and resistance to cancer therapeutics. Thus, identifying the mechanisms by which TOP2B levels are regulated may assist in the treatment of leukemia as well as the multitude of cancers that respond to TOP2 poisons. Our findings that RA resistance in APL cells can be overcome by targeting both the PRKCD and RA pathways may provide a basis for the rational design of novel therapies for not only RA-resistant APL, but other more common leukemias that have an increased TOP2B expression.
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